Antibodies and hematologic malignancies.
Over the last decade, monoclonal antibody therapy has transformed treatment of many hematologic malignancies. Optimizing the use of the existing agents and developing new agents will be critical to continuing these advances. This review summarizes existing data, new agents under investigation, and areas in which progress needs to be made in understanding mechanisms of action and resistance.
Smith
Mitchell R
MR
Lymphoma Service, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. M_smith@fccc.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000187:drug effects* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000922:Immunotoxins / Q000627:therapeutic use; D016499:Radioimmunotherapy; D000069283:Rituximab; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000922:Immunotoxins; D000069283:Rituximab